Comparative assessment of vascular function in autoimmune rheumatic diseases: Considerations of prevention and treatment

Autoimmunity Reviews

Volumn 10, Issue 7, 2011, Pages 416-425

  Soltész, Pál ^a   Kerekes, György ^a   Dér, Henriett ^a   Szücs, Gabriella ^a   Szántó, Sándor ^a   Kiss, Emese ^a,b   Bodolay, Edit ^a   Zeher, Margit ^a   Timár, Orsolya ^a   Szodoray, Péter ^c   Szegedi, Gyula ^d   Szekanecz, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

^c UNIVERSITY OF OSLO   (Norway)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Atherosclerosis; Autoimmune rheumatic diseases; Biologics; Cardiovascular disease; Endothelial dysfunction

Indexed keywords

ABATACEPT; ADALIMUMAB; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CELL RECEPTOR; CERTOLIZUMAB PEGOL; CHEMOKINE; CORTICOSTEROID; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTEINASE; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLOOD VESSEL FUNCTION; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COMMON CAROTID ARTERY; COMPARATIVE STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; INTIMA; MIXED CONNECTIVE TISSUE DISEASE; PULSE WAVE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; VASODILATATION;

AUTOIMMUNE DISEASES; HUMANS; MIXED CONNECTIVE TISSUE DISEASE; RHEUMATIC DISEASES; RISK FACTORS; SCLERODERMA, SYSTEMIC; SPONDYLARTHROPATHIES; VASCULAR DISEASES;

EID: 79955077207     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.01.004     Document Type: Review

References (202)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340(2):115-126.
2. Sherer Y., Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006, 2(2):99-106.
3. Shoenfeld Y., Gerli R., Doria A., Matsuura E., Cerinic M.M., Ronda N., et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005, 112(21):3337-3347.
4. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21(12):1876-1890.
5. Hansson G.K. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2009, 7(Suppl 1):328-331.
6. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54(23):2129-2138.
7. Soltesz P., Prohaszka Z., Fust G., Der H., Kerekes G., Szodoray P., et al. The autoimmune features of vasculopathies. Orv Hetil 2007, 148(Suppl 1):53-57.
8. Szekanecz Z. Pro-inflammatory cytokines in atherosclerosis. Isr Med Assoc J 2008, 10(7):529-530.
9. Hansson G.K., Jonasson L., Seifert P.S., Stemme S. Immune mechanisms in atherosclerosis. Arteriosclerosis 1989, 9(5):567-578.
10. Tervaert J.W. Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis. Clin Exp Immunol 2009, 156:377-385.
11. Abusamieh M., Ash J. Atherosclerosis and systemic lupus erythematosus. Cardiol Rev 2004, 12(5):267-275.
12. Alexandroff A.B., Pauriah M., Camp R.D., Lang C.C., Struthers A.D., Armstrong D.J. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009, 161(1):1-7.
13. Ames P.R. Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: a unifying 'membrane stress syndrome' hypothesis. Lupus 1994, 3(5):371-377.
14. Belizna C.C., Richard V., Thuillez C., Levesque H., Shoenfeld Y. Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmun Rev 2007, 7(1):46-51.
15. Bruce I.N., Gladman D.D., Urowitz M.B. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2000, 26(2):257-278.
16. Gerli R., Sherer Y., Bocci E.B., Vaudo G., Moscatelli S., Shoenfeld Y. Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors. Ann NY Acad Sci 2007, 1108:372-381.
17. Jara L.J., Medina G., Vera-Lastra O., Shoenfeld Y. Atherosclerosis and antiphospholipid syndrome. Clin Rev Allergy Immunol 2003, 25(1):79-88.
18. Matsuura E., Kobayashi K., Yasuda T., Koike T. Antiphospholipid antibodies and atherosclerosis. Lupus 1998, 7(Suppl 2):S135-S139.
19. Merrill J.T. The antiphospholipid syndrome and atherosclerosis: clue to pathogenesis. Curr Rheumatol Rep 2003, 5(5):401-406.
20. Sherer Y., Shoenfeld Y. Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis. Curr Atheroscler Rep 2001, 3(4):328-333.
21. Shoenfeld Y., Harats D., George J. Atherosclerosis and the antiphospholipid syndrome: a link unravelled?. Lupus 1998, 7(Suppl 2):S140-S143.
22. Szucs G., Timar O., Szekanecz Z., Der H., Kerekes G., Szamosi S., et al. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis-relevance for prevention of vascular complications. Rheumatology (Oxford) 2007, 46(5):759-762.
23. Kerekes G., Szekanecz Z., Der H., Sandor Z., Lakos G., Muszbek L., et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 2008, 35(3):398-406.
24. Soltesz P., Der H., Kerekes G., Szodoray P., Szucs G., Danko K., et al. A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases. Clin Rheumatol 2009, 28(6):655-662.
25. Szekanecz Z., Kerekes G., Der H., Sandor Z., Szabo Z., Vegvari A., et al. Accelerated atherosclerosis in rheumatoid arthritis. Ann NY Acad Sci 2007, 1108:349-358.
26. Szekanecz Z., Koch A.E. Vascular involvement in rheumatic diseases: 'vascular rheumatology'. Arthritis Res Ther 2008, 10(5):224.
27. Gonzalez-Juanatey C., Vazquez-Rodriguez T.R., Miranda-Filloy J.A., Dierssen T., Vaqueiro I., Blanco R., et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009, 88(6):358-365.
28. Heeneman S., Daemen M.J. Cardiovascular risks in spondyloarthritides. Curr Opin Rheumatol 2007, 19(4):358-362.
29. Peters M.J., Symmons D.P., McCarey D., Dijkmans B.A., Nicola P., Kvien T.K., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
30. Gladman D.D., Ang M., Su L., Tom B.D., Schentag C.T., Farewell V.T. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009, 68(7):1131-1135.
31. Gonzalez-Juanatey C., Llorca J., Miranda-Filloy J.A., Amigo-Diaz E., Testa A., Garcia-Porrua C., et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007, 57(2):287-293.
32. Vegh J., Soos G., Csipo I., Demeter N., Ben T., Dezso B., et al. Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost. Rheumatol Int 2006, 26(3):264-269.
33. Numano F. Vasa vasoritis, vasculitis and atherosclerosis. Int J Cardiol 2000, 75(Suppl 1):S1-S8. discussion S17-9.
34. Gerli R, Vaudo G, Bocci EB, Schillaci G, Alunno A, Luccioli F, et al. Functional impairment of the arterial wall in primary Sjogren's syndrome: combined action of immunologic and inflammatory factors. Arthritis Care Res (Hoboken) 2010;62(5):712-8.
35. Sarzi-Puttini P, Atzeni F, Gerli R, Bartoloni E, Doria A, Barskova T, et al. Cardiac involvement in systemic rheumatic diseases: an update. Autoimmun Rev 2010;9(12):849-52.
36. Sitia S., Atzeni F., Sarzi-Puttini P., Di Bello V., Tomasoni L., Delfino L., et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev 2009, 8(4):281-286.
37. Zardi E.M., Afeltra A. Endothelial dysfunction and vascular stiffness in systemic lupus erythematosus: are they early markers of subclinical atherosclerosis?. Autoimmun Rev 2010, 9(10):684-686.
38. Turiel M., Sitia S., Atzeni F., Tomasoni L., Gianturco L., Giuffrida M., et al. The heart in rheumatoid arthritis. Autoimmun Rev 2010, 9(6):414-418.
39. Giles J.T., Post W., Blumenthal R.S., Bathon J.M. Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2006, 2(6):320-329.
40. Tomasoni L., Sitia S., Borghi C., Cicero A.F., Ceconi C., Cecaro F., et al. Effects of treatment strategy on endothelial function. Autoimmun Rev 2010, 9(12):840-844.
41. Atzeni F., Turiel M., Caporali R., Cavagna L., Tomasoni L., Sitia S., et al. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev 2010, 9(12):835-839.
42. Kerekes G., Soltesz P., Der H., Veres K., Szabo Z., Vegvari A., et al. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann NY Acad Sci 2009, 1173:814-821.
43. Kerekes G., Soltesz P., Der H., Veres K., Szabo Z., Vegvari A., et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 2009, 28:705-710.
44. Szekanecz Z., Kerekes G., Soltesz P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol 2009, 5(12):677-684.
45. del Rincon I., Escalante A. Atherosclerotic cardiovascular disease in rheumatoid arthritis. Curr Rheumatol Rep 2003, 5(4):278-286.
46. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Miranda-Filloy J.A., Garcia-Porrua C., Llorca J., Martin J. Cardiovascular disease in rheumatoid arthritis. Biomed Pharmacother 2006, 60(10):673-677.
47. Kaplan M.J. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2006, 18(3):289-297.
48. Kaplan M.J. Endothelial damage and autoimmune diseases. Autoimmunity 2009, 42(7):561-562.
49. Van Doornum S., McColl G., Wicks I.P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?. Arthritis Rheum 2002, 46(4):862-873.
50. Klareskog L., Padyukov L., Lorentzen J., Alfredsson L. Mechanisms of disease: genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nat Clin Pract Rheumatol 2006, 2(8):425-433.
51. Padyukov L., Silva C., Stolt P., Alfredsson L., Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004, 50(10):3085-3092.
52. Szodoray P., Szabo Z., Kapitany A., Gyetvai A., Lakos G., Szanto S., et al. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2010, 9:140-143.
53. Dessein P.H., Tobias M., Veller M.G. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2006, 33(12):2425-2432.
54. Gonzalez-Gay M.A., Llorca J., Garcia-Unzueta M.T., Gonzalez-Juanatey C., De Matias J.M., Martin J., et al. High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin Exp Rheumatol 2008, 26(4):596-603.
55. Konrad A., Lehrke M., Schachinger V., Seibold F., Stark R., Ochsenkuhn T., et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 2007, 19(12):1070-1074.
56. Tong K.M., Shieh D.C., Chen C.P., Tzeng C.Y., Wang S.P., Huang K.C., et al. Leptin induces IL-8 expression via leptin receptor, IRS-1, PI3K, Akt cascade and promotion of NF-kappaB/p300 binding in human synovial fibroblasts. Cell Signal 2008, 20(8):1478-1488.
57. Dessein P.H., Joffe B.I., Stanwix A.E. Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. J Rheumatol 2003, 30(7):1403-1405.
58. Chung C.P., Oeser A., Solus J.F., Avalos I., Gebretsadik T., Shintani A., et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008, 196(2):756-763.
59. Surdacki A., Martens-Lobenhoffer J., Wloch A., Gluszko P., Rakowski T., Dubiel J.S., et al. Plasma asymmetric dimethylarginine is related to anticitrullinated protein antibodies in rheumatoid arthritis of short duration. Metabolism 2009, 58(3):316-318.
60. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008, 121(10 Suppl 1):S21-S31.
61. Gonzalez-Gay M.A., Garcia-Unzueta M.T., De Matias J.M., Gonzalez-Juanatey C., Garcia-Porrua C., Sanchez-Andrade A., et al. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006, 24(4):373-379.
62. Szekanecz Z., Koch A.E. Cell-cell interactions in synovitis. Endothelial cells and immune cell migration. Arthritis Res 2000, 2(5):368-373.
63. Szekanecz Z., Szegedi G., Koch A.E. Cellular adhesion molecules in rheumatoid arthritis: regulation by cytokines and possible clinical importance. J Investig Med 1996, 44(4):124-135.
64. Bevilacqua M.P., Nelson R.M., Mannori G., Cecconi O. Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med 1994, 45:361-378.
65. Farragher T.M., Goodson N.J., Naseem H., Silman A.J., Thomson W., Symmons D., et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008, 58(2):359-369.
66. Szekanecz Z., Koch A.E. Update on synovitis. Curr Rheumatol Rep 2001, 3(1):53-63.
67. Szekanecz Z., Koch A.E. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007, 19(3):289-295.
68. Mohammed F.F., Smookler D.S., Khokha R. Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rheum Dis 2003, 62(Suppl 2):ii43-ii47.
69. Creemers E.E., Cleutjens J.P., Smits J.F., Daemen M.J. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circ Res 2001, 89(3):201-210.
70. Skotnicki J.S., Zask A., Nelson F.C., Albright J.D., Levin J.I. Design and synthetic considerations of matrix metalloproteinase inhibitors. Ann NY Acad Sci 1999, 878:61-72.
71. Gerli R., Schillaci G., Giordano A., Bocci E.B., Bistoni O., Vaudo G., et al. CD4+CD28? T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004, 109(22):2744-2748.
72. Sherer Y., Gerli R., Gilburd B., Bartoloni Bocci E., Vaudo G., Mannarino E., et al. Thickened carotid artery intima-media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies. Lupus 2007, 16(4):259-264.
73. Tobon G.J., Alard J.E., Youinou P., Jamin C. Are autoantibodies triggering endothelial cell apoptosis really pathogenic?. Autoimmun Rev 2009, 8(7):605-610.
74. Avouac J., Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother 2008, 9(7):1121-1128.
75. Salmon J.E., Roman M.J. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 2008, 121(10 Suppl 1):S3-S8.
76. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39(2):257-265.
77. Kanters S.D., Algra A., van Leeuwen M.S., Banga J.D. Reproducibility of in vivo carotid intima-media thickness measurements: a review. Stroke 1997, 28(3):665-671.
78. Baulmann J., Schillings U., Rickert S., Uen S., Dusing R., Illyes M., et al. A new oscillometric method for assessment of arterial stiffness: comparison with tonometric and piezo-electronic methods. J Hypertens 2008, 26(3):523-528.
79. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Vazquez-Rodriguez T.R., Martin J., Llorca J. Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum 2008, 38(2):67-70.
80. Atzeni F., Turiel M., Hollan I., Meroni P., Sitia S., Tomasoni L., et al. Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. Autoimmun Rev 2010, 9(12):845-848.
81. Gonzalez-Juanatey C., Llorca J., Vazquez-Rodriguez T.R., Diaz-Varela N., Garcia-Quiroga H., Gonzalez-Gay M.A. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 2008, 59(12):1821-1824.
82. Kerekes G., Soltesz P., Der H., Veres K., Szabo Z., Vegvari A., et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 2009, 28(6):705-710.
83. Sidiropoulos P.I., Siakka P., Pagonidis K., Raptopoulou A., Kritikos H., Tsetis D., et al. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 2009, 38(1):6-10.
84. Van Doornum S., McColl G., Jenkins A., Green D.J., Wicks I.P. Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 2003, 48(1):72-80.
85. Sitia S., Tomasoni L., Atzeni F., Ambrosio G., Cordiano C., Catapano A., et al. From endothelial dysfunction to atherosclerosis. Autoimmun Rev 2010, 9(12):830-834.
86. Abu-Shakra M., Polychuck I., Szendro G., Bolotin A., Jonathan B.S., Flusser D., et al. Duplex study of the carotid and femoral arteries of patients with rheumatoid arthritis: a controlled study. Semin Arthritis Rheum 2005, 35(1):18-23.
87. Daza L., Aguirre M., Jimenez M., Herrera R., Bollain J.J. Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors. Clin Rheumatol 2007, 26(4):533-537.
88. Del Rincon I., Williams K., Stern M.P., Freeman G.L., O'Leary D.H., Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003, 48(7):1833-1840.
89. Gerli R., Bartoloni Bocci E., Sherer Y., Vaudo G., Moscatelli S., Shoenfeld Y. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67(5):724-725.
90. Gonzalez-Juanatey C., Llorca J., Martin J., Gonzalez-Gay M.A. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 2009, 38(5):366-371.
91. Gerli R., Sherer Y., Vaudo G., Schillaci G., Gilburd B., Giordano A., et al. Early atherosclerosis in rheumatoid arthritis: effects of smoking on thickness of the carotid artery intima media. Ann NY Acad Sci 2005, 1051:281-290.
92. Kobayashi H., Giles J.T., Polak J.F., Blumenthal R.S., Leffell M.S., Szklo M., et al. Increased prevalence of carotid artery atherosclerosis in rheumatoid arthritis is artery-specific. J Rheumatol 2010, 37(4):730-739.
93. Giles J.T., Szklo M., Post W., Petri M., Blumenthal R.S., Lam G., et al. Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis. Arthritis Res Ther 2009, 11(2):R36.
94. Peters M.J., van Eijk I.C., Smulders Y.M., Serne E., Dijkmans B.A., van der Horst-Bruinsma I.E., et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010, 37:161-166.
95. Han C., Robinson D.W., Hackett M.V., Paramore L.C., Fraeman K.H., Bala M.V. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006, 33(11):2167-2172.
96. Hahn B.H., Grossman J., Chen W., McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007, 28(2-3):69-75.
97. Malesci D., Niglio A., Mennillo G.A., Buono R., Valentini G., La Montagna G. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 2007, 26(5):710-714.
98. Kiortsis D.N., Mavridis A.K., Filippatos T.D., Vasakos S., Nikas S.N., Drosos A.A. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006, 33(5):921-923.
99. Mathieu S., Dubost J.J., Tournadre A., Malochet-Guinamand S., Ristori J.M., Soubrier M. Effects of 14weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Joint Bone Spine 2010, 77:50-52.
100. van Eijk I.C., de Vries M.K., Levels J.H., Peters M.J., Huizer E.E., Dijkmans B.A., et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009, 60(5):1324-1330.
101. Dominguez-Lopez M.L., Ortega-Ortega Y., Manriquez-Raya J.C., Burgos-Vargas R., Vega-Lopez A., Garcia-Latorre E. Antibodies against recombinant heat shock proteins of 60kDa from enterobacteria in the sera and synovial fluid of HLA-B27 positive ankylosing spondylitis patients. Clin Exp Rheumatol 2009, 27(4):626-632.
102. Sari I., Kebapcilar L., Alacacioglu A., Bilgir O., Yildiz Y., Taylan A., et al. Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis. Intern Med 2009, 48(16):1363-1368.
103. Pieringer H. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006, 45(10):1319.
104. Sari I., Okan T., Akar S., Cece H., Altay C., Secil M., et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006, 45(3):283-286.
105. Choe J.Y., Lee M.Y., Rheem I., Rhee M.Y., Park S.H., Kim S.K. No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 2008, 75(5):548-553.
106. Mathieu S., Joly H., Baron G., Tournadre A., Dubost J.J., Ristori J.M., et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 2008, 47(8):1203-1207.
107. Gonzalez-Gay M.A., Vazquez-Rodriguez T.R., Gonzalez-Juanatey C., Llorca J. Subclinical atherosclerosis in patients with psoriatic arthritis. J Rheumatol 2008, 35(10):2070-2071. author reply 2071.
108. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Vazquez-Rodriguez T.R., Gomez-Acebo I., Miranda-Filloy J.A., Paz-Carreira J., et al. Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2009, 39(3):157-162.
109. Eder L., Zisman D., Barzilai M., Laor A., Rahat M., Rozenbaum M., et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 2008, 35(5):877-882.
110. Gonzalez-Juanatey C., Llorca J., Amigo-Diaz E., Dierssen T., Martin J., Gonzalez-Gay M.A. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007, 57(6):1074-1080.
111. Kimhi O., Caspi D., Bornstein N.M., Maharshak N., Gur A., Arbel Y., et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007, 36(4):203-209.
112. Tam L.S., Shang Q., Li E.K., Tomlinson B., Chu T.T., Li M., et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008, 59(9):1322-1331.
113. El-Mongy S., Fathy H., Abdelaziz A., Omran E., George S., Neseem N., et al. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. J Eur Acad Dermatol Venereol 2010, 24:661-666.
114. Christophers E. Comorbidities in psoriasis. Clin Dermatol 2007, 25(6):529-534.
115. Abou-Raya A., Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006, 5(5):331-337.
116. Boumpas D.T., Austin H.A., Fessler B.J., Balow J.E., Klippel J.H., Lockshin M.D. Systemic lupus erythematosus: emerging concepts. Part 1: renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995, 122(12):940-950.
117. Kiss E., Fazekas B., Tarr T., Muszbek L., Zeher M., Szegedi G. Lipid profile in patients with systemic lupus erythematosus, with special focus on lipoprotein(a) in lupus nephritis. Orv Hetil 2004, 145(5):217-222.
118. Zampieri S., Iaccarino L., Ghirardello A., Tarricone E., Arienti S., Sarzi-Puttini P., et al. Systemic lupus erythematosus, atherosclerosis, and autoantibodies. Ann NY Acad Sci 2005, 1051:351-361.
119. Tarr T., Lakos G., Bhattoa H.P., Soltesz P., Shoenfeld Y., Szegedi G., et al. Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up. Clin Rev Allergy Immunol 2007, 32(2):131-137.
120. Sherer Y., Zinger H., Shoenfeld Y. Atherosclerosis in systemic lupus erythematosus. Autoimmunity 2010, 43(1):98-102.
121. Smith P.P., Gordon C. Systemic lupus erythematosus: clinical presentations. Autoimmun Rev 2010, 10(1):43-45.
122. Salmon J.E., Roman M.J. Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. Curr Opin Rheumatol 2001, 13(5):341-344.
123. Agarwal S., Elliott J.R., Manzi S. Atherosclerosis risk factors in systemic lupus erythematosus. Curr Rheumatol Rep 2009, 11(4):241-247.
124. Doria A., Shoenfeld Y., Wu R., Gambari P.F., Puato M., Ghirardello A., et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003, 62(11):1071-1077.
125. Colombo B.M., Cacciapaglia F., Puntoni M., Murdaca G., Rossi E., Rodriguez G., et al. Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev 2009, 8(4):309-315.
126. Kiss E., Seres I., Tarr T., Kocsis Z., Szegedi G., Paragh G. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann NY Acad Sci 2007, 1108:83-91.
127. Petri M., Perez-Gutthann S., Spence D., Hochberg M.C. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992, 93(5):513-519.
128. Hua X., Su J., Svenungsson E., Hurt-Camejo E., Jensen-Urstad K., Angelin B., et al. Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE-related cardiovascular disease. Scand J Rheumatol 2009, 38(3):184-189.
129. Soltesz P., Szekanecz Z., Kiss E., Shoenfeld Y. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev 2007, 6(6):379-386.
130. Bassi N., Ghirardello A., Iaccarino L., Zampieri S., Rampudda M.E., Atzeni F., et al. OxLDL/beta2GPI-anti-oxLDL/beta2GPI complex and atherosclerosis in SLE patients. Autoimmun Rev 2007, 7(1):52-58.
131. Lopez L.R., Simpson D.F., Hurley B.L., Matsuura E. OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement. Ann NY Acad Sci 2005, 1051:313-322.
132. Fischer K., Brzosko M., Walecka A., Ostanek L., Sawicki M. Antiendothelial cell antibodies as a risk factor of atherosclerosis in systemic lupus erythematosus. Ann Acad Med Stetin 2006, 52(Suppl 2):95-99.
133. Gustafsson J., Gunnarsson I., Borjesson O., Pettersson S., Moller S., Fei G.Z., et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. Arthritis Res Ther 2009, 11(6):R186.
134. McMahon M., Hahn B.H. Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol 2007, 19(6):633-639.
135. Horvath L., Czirjak L., Fekete B., Jakab L., Prohaszka Z., Cervenak L., et al. Levels of antibodies against C1q and 60kDa family of heat shock proteins in the sera of patients with various autoimmune diseases. Immunol Lett 2001, 75(2):103-109.
136. Barnes E.V., Narain S., Naranjo A., Shuster J., Segal M.S., Sobel E.S., et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005, 14(8):576-582.
137. Burger D., Dayer J.M. High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation?. Autoimmun Rev 2002, 1(1-2):111-117.
138. Lopez L.R., Salazar-Paramo M., Palafox-Sanchez C., Hurley B.L., Matsuura E., Garcia-De La Torre I. Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus 2006, 15(2):80-86.
139. Reichlin M., Fesmire J., Quintero-Del-Rio A.I., Wolfson-Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002, 46(11):2957-2963.
140. Soltesz P., Veres K., Laczik R., Der H., Csipo I., Timar O., et al. Evaluation of antibodies to oxidized low-density lipoprotein and assessment of C-reactive protein in acute coronary syndrome and stable coronary artery disease. Thromb Haemost 2007, 98(2):413-419.
141. Laczik R., Szodoray P., Veres K., Lakos G., Sipka S., Szegedi G., et al. Oxidized LDL induces in vitro lymphocyte activation in antiphospholipid syndrome. Autoimmunity 2010, 43(4):334-339.
142. de Leeuw K., Freire B., Smit A.J., Bootsma H., Kallenberg C.G., Bijl M. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 2006, 15(10):675-682.
143. Chung C.P., Long A.G., Solus J.F., Rho Y.H., Oeser A., Raggi P., et al. Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus 2009, 18(9):799-806.
144. Zhang H.Y., Bao S.M., Shou W.L., Luan H.X., Zhang Y., Feng X., et al. Expression of matrix metalloproteinase-1 mRNA in peripheral blood mononuclear cells of systemic lupus erythematosus patients and its relationship with atherosclerosis. Chin Med J (Engl) 2009, 122(21):2593-2597.
145. Ghosh P., Kumar A., Kumar S., Aggarwal A., Sinha N., Misra R. Subclinical atherosclerosis and endothelial dysfunction in young South-Asian patients with systemic lupus erythematosus. Clin Rheumatol 2009, 28(11):1259-1265.
146. Kiss E., Soltesz P., Der H., Kocsis Z., Tarr T., Bhattoa H., et al. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun 2006, 27(4):211-217.
147. Palmieri V., Migliaresi P., Orefice M., Lupo T., Di Minno M.N., Valentini G., et al. High prevalence of subclinical cardiovascular abnormalities in patients with systemic lupus erythematosus in spite of a very low clinical damage index. Nutr Metab Cardiovasc Dis 2009, 19(4):234-240.
148. Svenungsson E., Cederholm A., Jensen-Urstad K., Fei G.Z., de Faire U., Frostegard J. Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus. Scand J Rheumatol 2008, 37(5):352-359.
149. Bijl M. Endothelial activation, endothelial dysfunction and premature atherosclerosis in systemic autoimmune diseases. Neth J Med 2003, 61(9):273-277.
150. Cacciapaglia F., Zardi E.M., Coppolino G., Buzzulini F., Margiotta D., Arcarese L., et al. Stiffness parameters, intima-media thickness and early atherosclerosis in systemic lupus erythematosus patients. Lupus 2009, 18(3):249-256.
151. Colombo B.M., Murdaca G., Caiti M., Rodriguez G., Grassia L., Rossi E., et al. Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus. Ann NY Acad Sci 2007, 1108:121-126.
152. Schanberg L.E., Sandborg C., Barnhart H.X., Ardoin S.P., Yow E., Evans G.W., et al. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum 2009, 60(5):1496-1507.
153. Thompson T., Sutton-Tyrrell K., Wildman R.P., Kao A., Fitzgerald S.G., Shook B., et al. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 2008, 58(3):835-842.
154. Svenungsson E., Jensen-Urstad K., Heimburger M., Silveira A., Hamsten A., de Faire U., et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001, 104(16):1887-1893.
155. Kiani A.N., Magder L., Petri M. Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. J Rheumatol 2008, 35(7):1300-1306.
156. Soltesz P., Veres K., Lakos G., Kiss E., Muszbek L., Szegedi G. Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients. Lupus 2003, 12(4):302-307.
157. Ames P.R., Margarita A., Alves J.D. Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rev Allergy Immunol 2009, 37(1):29-35.
158. Baker W.F., Bick R.L. The clinical spectrum of antiphospholipid syndrome. Hematol Oncol Clin North Am 2008, 22(1):33-52. v-vi.
159. Veres K., Lakos G., Kerenyi A., Szekanecz Z., Szegedi G., Shoenfeld Y., et al. Antiphospholipid antibodies in acute coronary syndrome. Lupus 2004, 13(6):423-427.
160. Hughes G.R. Hughes Syndrome (the antiphospholipid syndrome): ten clinical lessons. Autoimmun Rev 2008, 7(3):262-266.
161. Der H., Kerekes G., Veres K., Szodoray P., Toth J., Lakos G., et al. Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus 2007, 16(7):497-503.
162. Asherson R.A., Cervera R., Shoenfeld Y. Peripheral vascular occlusions leading to gangrene and amputations in antiphospholipid antibody positive patients. Ann NY Acad Sci 2007, 1108:515-529.
163. Ames P.R., Margarita A., Sokoll K.B., Weston M., Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 2005, 64(2):315-317.
164. Soltesz P., Der H., Veres K., Laczik R., Sipka S., Szegedi G., et al. Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction. Rheumatology (Oxford) 2008, 47(11):1628-1634.
165. Alves J.D., Ames P.R. Atherosclerosis, oxidative stress and auto-antibodies in systemic lupus erythematosus and primary antiphospholipid syndrome. Immunobiology 2003, 207(1):23-28.
166. Bilora F., Sartori M.T., Zanon E., Campagnolo E., Arzenton M., Rossato A. Flow-mediated arterial dilation in primary antiphospholipid syndrome. Angiology 2009, 60(1):104-107.
167. Ames P.R., Margarita A., Delgado Alves J., Tommasino C., Iannaccone L., Brancaccio V. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 2002, 11(4):208-214.
168. Jimenez S., Garcia-Criado M.A., Tassies D., Reverter J.C., Cervera R., Gilabert M.R., et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 2005, 44(6):756-761.
169. Muller-Ladner U., Distler O., Ibba-Manneschi L., Neumann E., Gay S. Mechanisms of vascular damage in systemic sclerosis. Autoimmunity 2009, 42(7):587-595.
170. Szamosi S., Csiki Z., Szomjak E., Szolnoki E., Szoke G., Szekanecz Z., et al. Plasma homocysteine levels, the prevalence of methylenetetrahydrofolate reductase gene C677T polymorphism and macrovascular disorders in systemic sclerosis: risk factors for accelerated macrovascular damage?. Clin Rev Allergy Immunol 2009, 36(2-3):145-149.
171. Czirjak L., Kumanovics G., Varju C., Nagy Z., Pakozdi A., Szekanecz Z., et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008, 67(1):59-63.
172. Nussinovitch U., Shoenfeld Y. Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality. Autoimmun Rev Sep 21 2010, (Epub).
173. Pignone A., Scaletti C., Matucci-Cerinic M., Vazquez-Abad D., Meroni P.L., Del Papa N., et al. Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 1998, 16(5):527-532.
174. Koch A.E., Kronfeld-Harrington L.B., Szekanecz Z., Cho M.M., Haines G.K., Harlow L.A., et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology 1993, 61(5-6):239-246.
175. Gruschwitz M., von den Driesch P., Kellner I., Hornstein O.P., Sterry W. Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 1992, 27(2 Pt 1):169-177.
176. Kodera M., Hayakawa I., Komura K., Yanaba K., Hasegawa M., Takehara K., et al. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations. J Rheumatol 2005, 32(4):629-636.
177. Hettema M.E., Zhang D., de Leeuw K., Stienstra Y., Smit A.J., Kallenberg C.G., et al. Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors. Arthritis Res Ther 2008, 10(2):R49.
178. Bartoli F., Blagojevic J., Bacci M., Fiori G., Tempestini A., Conforti M.L., et al. Flow-mediated vasodilation and carotid intima-media thickness in systemic sclerosis. Ann NY Acad Sci 2007, 1108:283-290.
179. Cypiene A., Laucevicius A., Venalis A., Dadoniene J., Ryliskyte L., Petrulioniene Z., et al. The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function. Clin Rheumatol 2008, 27(12):1517-1522.
180. Andersen G.N., Mincheva-Nilsson L., Kazzam E., Nyberg G., Klintland N., Petersson A.S., et al. Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. Arthritis Rheum 2002, 46(5):1324-1332.
181. Timar O., Soltesz P., Szamosi S., Der H., Szanto S., Szekanecz Z., et al. Increased arterial stiffness as the marker of vascular involvement in systemic sclerosis. J Rheumatol 2008, 35(7):1329-1333.
182. Constans J., Germain C., Gosse P., Taillard J., Tiev K., Delevaux I., et al. Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS study. J Hypertens 2007, 25(9):1900-1906.
183. Moyssakis I., Gialafos E., Vassiliou V., Taktikou E., Katsiari C., Papadopoulos D.P., et al. Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement. Rheumatology (Oxford) 2005, 44(2):251-254.
184. Soltesz P., Bereczki D., Szodoray P., Magyar M.T., Der H., Csipo I., et al. Endothelial cell markers reflecting endothelial cell dysfunction in patients with mixed connective tissue disease. Arthritis Res Ther 2010, 12(3):R78.
185. Vegh J., Szodoray P., Kappelmayer J., Csipo I., Udvardy M., Lakos G., et al. Clinical and immunoserological characteristics of mixed connective tissue disease associated with pulmonary arterial hypertension. Scand J Immunol 2006, 64(1):69-76.
186. Bodolay E., Csipo I., Gal I., Sipka S., Gyimesi E., Szekanecz Z., et al. Anti-endothelial cell antibodies in mixed connective tissue disease: frequency and association with clinical symptoms. Clin Exp Rheumatol 2004, 22(4):409-415.
187. Kanazawa M., Wada Y., Ohno T., In H., Yahata K., Izumi J., et al. Mixed connective tissue disease associated with antineutrophil cytoplasmic antibodies against proteinase-3 and systemic atherosclerosis: a case report. Clin Rheumatol 2004, 23(5):456-459.
188. Bodolay E., Seres I., Szodoray P., Csipo I., Jakab Z., Vegh J., et al. Evaluation of paraoxonase activity in patients with mixed connective tissue disease. J Rheumatol 2008, 35(2):237-243.
189. Vaudo G., Bocci E.B., Shoenfeld Y., Schillaci G., Wu R., Del Papa N., et al. Precocious intima-media thickening in patients with primary Sjogren's syndrome. Arthritis Rheum 2005, 52(12):3890-3897.
190. Peters M.J., van Halm V.P., Voskuyl A.E., Smulders Y.M., Boers M., Lems W.F., et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009, 61(11):1571-1579.
191. Bruce I.N. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?. Best Pract Res Clin Rheumatol 2005, 19(5):823-838.
192. Hall F.C., Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin?. Rheumatology (Oxford) 2005, 44(12):1473-1482.
193. Suissa S., Bernatsky S., Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006, 55(4):531-536.
194. van Halm V.P., Nurmohamed M.T., Twisk J.W., Dijkmans B.A., Voskuyl A.E. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006, 8(5):R151.
195. Maxwell S.R., Moots R.J., Kendall M.J. Corticosteroids: do they damage the cardiovascular system?. Postgrad Med J 1994, 70(830):863-870.
196. Nashel D.J. Is atherosclerosis a complication of long-term corticosteroid treatment?. Am J Med 1986, 80(5):925-929.
197. Reiss A.B., Carsons S.E., Anwar K., Rao S., Edelman S.D., Zhang H., et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 2008, 58(12):3675-3683.
198. van Ede A.E., Laan R.F., Blom H.J., Boers G.H., Haagsma C.J., Thomas C.M., et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 2002, 41(6):658-665.
199. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996, 25(4):191-193.
200. van Leeuwen M., Damoiseaux J., Duijvestijn A., Tervaert J.W. The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis. Autoimmun Rev 2009, 9(1):53-57.
201. Garces S.P., Parreira Santos M.J., Vinagre F.M., Roque R.M., da Silva J.A. Anti-tumour necrosis factor agents and lipid profile: a class effect?. Ann Rheum Dis 2008, 67(6):895-896.
202. Gonzalez-Gay M.A., De Matias J.M., Gonzalez-Juanatey C., Garcia-Porrua C., Sanchez-Andrade A., Martin J., et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006, 24(1):83-86.